In such cases, GLP-1 receptor agonists (injectable or oral) are integral options for dual or triple therapy (e.g., metformin + GLP-1 RA; SGLT2 inhibitor + GLP-1 RA; metformin + SGLT2 inhibitor + GLP-1 RA), given their robust A1C-lowering efficacy, favorable weight profile, and low intrinsic hypoglycemia risk [20]. This evidence concerns the gene SLC5A2 and Hypoglycemia.